Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Vergis N, et al. Among authors: milojkovic d. Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z. Trials. 2021. PMID: 33845867 Free PMC article.
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K. Innes AJ, et al. Among authors: milojkovic d. Bone Marrow Transplant. 2013 Oct;48(10):1324-8. doi: 10.1038/bmt.2013.69. Epub 2013 May 20. Bone Marrow Transplant. 2013. PMID: 23686098
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G, Apperley J, Milojkovic D. Innes AJ, et al. Among authors: milojkovic d. Br J Haematol. 2020 Aug;190(4):e198-e200. doi: 10.1111/bjh.16979. Epub 2020 Jul 26. Br J Haematol. 2020. PMID: 32593183 Free PMC article. Clinical Trial. No abstract available.
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook LB, O'Dell G, Vourvou E, Palanicawandar R, Marks S, Milojkovic D, Apperley JF, Loaiza S, Claudiani S, Bua M, Hockings C, Macdonald D, Chaidos A, Pavlu J, Cooper N, Fidler S, Randell P, Innes AJ. Cook LB, et al. Among authors: milojkovic d. Nat Commun. 2022 Nov 14;13(1):6922. doi: 10.1038/s41467-022-34657-z. Nat Commun. 2022. PMID: 36376307 Free PMC article.
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.
Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Gabriel IH, et al. Among authors: milojkovic d. Blood. 2010 Sep 23;116(12):2033-9. doi: 10.1182/blood-2010-03-273706. Epub 2010 Jun 18. Blood. 2010. PMID: 20562327 Free PMC article.
Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.
Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Garland P, et al. Among authors: milojkovic d. Biol Blood Marrow Transplant. 2011 May;17(5):632-9. doi: 10.1016/j.bbmt.2010.08.002. Epub 2010 Aug 11. Biol Blood Marrow Transplant. 2011. PMID: 20708085 Free article.
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. de Lavallade H, et al. Among authors: milojkovic d. Haematologica. 2011 Feb;96(2):307-14. doi: 10.3324/haematol.2010.032664. Epub 2010 Oct 22. Haematologica. 2011. PMID: 20971824 Free PMC article.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: milojkovic d. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
136 results